ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1948 participants.

Also called NCT03735667

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,948 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03735667
Main results
  • ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial Lancet (London, England), 2025-06-07 DOI, PubMed 40412426

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03735667. Randomized; no masking; primary purpose treatment. Start 2019-06-10 (actual); primary completion 2024-06-14 (actual). Results posted on 2025-04-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
Condition
Aortic Stenosis
Intervention (Device)
ACURATE neo2™ Transfemoral TAVR System
Intervention (Device)
Medtronic CoreValve TAVR System
Intervention (Device)
Edwards SAPIEN 3 TAVR System
Intervention (Device)
ACURATE Prime™ Transfemoral TAVR System XL
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct03735667
Content hash
62c5ee19be10b0126ef4a59561e4b55fbbd06af969df3ab264dfe82a1b482080